

**NEUROENDOCRINE
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION**

VENUE: ROSSETTI ROOM, DELTA CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 27TH, 2013

TIME: 10:30 – 11:15

CHAIRS: DR. TIM ASMIS & DR. HAGEN KENNECKE

- 10:30 WELCOME AND INTRODUCTION **DR. H. KENNECKE AND DR. T. ASMIS**
- 10:30 APPROVED/ACTIVE TRIALS
- NEC.2 (CALGB 80701):** RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS
- DR. H. KENNECKE**
- 10:45 CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS
- ALLIANCE 021202 (CALGB 81103):** PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS **DR. T. ASMIS**
- ECOG2211:** A RANDOMIZED STUDY OF TEMOZOLOMIDE OR TEMOZOLOMIDE-CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS **DR. T. ASMIS**
- INTERGROUP TASK FORCE UPDATE **DR. T. ASMIS**
- 11:15 CLOSING REMARKS